Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Randy Schmid who wrote (2572)	10/30/1997 12:55:00 PM
From: Joe E.	Read Replies (1) \| Respond to of 6136

Randy: re your"Currently own options expiring in February - after earnings, and in May." I would be quite surprised if there was not a good jump on European approval news. This, IMO, should be before Feb or May options expire. However, if you are pretty far out of the money, it may not hit your targets. Next quarters Merck and Agouron reports should both be positive for the stock, in terms of drug sales -- can't say about earnings.